Related Experiment Video
Updated: Apr 5, 2026
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma
Rossella Farra1, Mario Grassi1, Gabriele Grassi1
1Rossella Farra, Mario Grassi, Department of Industrial Engineering and Information Technology, University of Trieste, 34100 Trieste, Italy.
Abstract:
Hepatocellular carcinoma (HCC) is the predominant form of primary liver cancer and represents the third leading cause of cancer-related death worldwide. Current available therapeutic approaches are poorly effective, especially for the advanced forms of the disease. In the last year, short double stranded RNA molecules termed small interfering RNAs (siRNAs) and micro interfering RNAs (miRNA), emerged as interesting molecules with potential therapeutic value for HCC. The practical use of these molecules is however limited by the identification of optimal molecular targets and especially by the lack of effective and targeted HCC delivery systems. Here we focus our discussion on the most recent advances in the identification of siRNAs/miRNAs molecular targets and on the development of suitable siRNA/miRNAs delivery systems.
Insights
Small interfering RNAs (siRNAs) and micro interfering RNAs (miRNAs) show therapeutic promise for liver cancer (HCC). Advances in identifying molecular targets and developing effective delivery systems are crucial for their clinical application in HCC treatment.
Area of Science:
- Oncology
- Molecular Biology
- RNA Therapeutics
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally, with limited treatment options for advanced stages.
- Current therapies for HCC are often ineffective, highlighting the need for novel treatment strategies.
- RNA interference (RNAi) molecules, including siRNAs and miRNAs, have emerged as potential therapeutic agents for HCC.
Discussion:
- The clinical utility of siRNAs and miRNAs in HCC is hindered by challenges in identifying optimal molecular targets.
- Effective and targeted delivery systems are essential for the successful application of these RNA-based therapies in HCC.
- Recent research focuses on overcoming these limitations by advancing target identification and delivery system development.
Key Insights:
- siRNAs and miRNAs represent a promising frontier in HCC therapy.
- Progress in identifying specific molecular targets is critical for siRNA/miRNA efficacy.
- Development of advanced delivery platforms is paramount for successful HCC treatment using RNAi.
Outlook:
- Future research will likely focus on refining siRNA/miRNA target selection for HCC.
- Innovations in nanotechnology and delivery vectors are expected to enhance HCC treatment outcomes.
- The integration of target identification and delivery system development will accelerate the clinical translation of RNAi-based HCC therapies.
More Related Videos
09:18TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents
Published on: June 2, 2016
04:29Efficient Gene Knockdown in the Liver via Intrasplenic Injection of Adeno-Associated Virus Serotype 8 (AAV8)-Delivered Small Hairpin RNA
Published on: November 1, 2024
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:15Experimental RNAi
02:30Small interfering RNAs (siRNA)
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:23RNA Interference
01:30Inhibitors of Viral Protein Synthesis